<p>Sonoma Pharmaceuticals, Inc.（“公司” 或 “Sonoma Pharmaceuticals”）（NASDAQ:SNOA）是一家全球領先的次氯酸（HOCl）技術醫療保健公司，今天宣佈其公開發行的定價，該發行以固定承諾的方式進行，預計公司將獲得約 400 萬美元的總收益，未扣除公司需支付的費用和其他開支。此次發行包括 2,962,963 股普通股和 2,962,963 個認股權證。每股普通股的銷售價格為 1.35 美元。認股權證的行使價格為每股 1.35 美元。</p>
<p>此外，Sonoma Pharmaceuticals 已授予 Dawson James Securities 一個為期 45 天的選擇權，以購買最多 15% 在此次發行中出售的股份或認股權證，僅用於覆蓋超額配售（如有）。</p>
<p>此次發行預計將於 2026 年 4 月 27 日完成，前提是滿足慣常的交割條件。</p>
<p>公司預計將把此次發行的淨收益用於一般企業用途，包括營運資金。</p>
<p>Dawson James Securities 擔任此次發行的唯一賬簿管理人。</p>
<p>與此次證券發行相關的 S-1 表格註冊聲明已向美國證券交易委員會（SEC）提交，並於 2026 年 4 月 23 日獲得 SEC 的有效聲明。此次發行僅通過招股説明書進行。有關擬議交易條款的最終招股説明書可在 SEC 的網站 www.sec.gov 上獲取，或通過聯繫 Dawson James Securities 獲取。本新聞稿不構成出售這些證券的要約或購買這些證券的要約邀請，也不應在任何州或司法管轄區進行證券的銷售，除非在任何此類州或司法管轄區的證券法下進行註冊或資格審查。</p>
<p><strong>關於 Sonoma Pharmaceuticals</strong></p>
<p>Sonoma Pharmaceuticals 是一家全球醫療保健領導者，專注於開發和生產穩定的次氯酸（HOCl）產品，廣泛應用於傷口護理、眼部護理、皮膚病、足病、動物醫療和無毒消毒劑。Sonoma 的產品經過臨牀驗證，能夠安全有效地減少瘙癢、疼痛、疤痕和刺激，而不會損害健康組織。對 HOCl 的體外和臨牀研究表明，它能夠安全管理皮膚擦傷、裂傷、輕微刺激、切口和完整皮膚。Sonoma 的產品在全球 55 個國家通過直接銷售或合作伙伴銷售，公司積極尋求新的分銷合作伙伴。公司的主要辦公室位於科羅拉多州博爾德，製造業務位於墨西哥瓜達拉哈拉。歐洲市場營銷和銷售總部位於荷蘭羅 ermond。更多信息請訪問 www.sonomapharma.com。</p>
<p><strong>前瞻性聲明</strong></p>
<p>除本文中的歷史信息外，本新聞稿中所述事項屬於 1995 年《私人證券訴訟改革法案》“安全港” 條款下的前瞻性聲明，包括關於 Sonoma Pharmaceuticals, Inc.及其子公司的商業和技術進展及未來財務表現的聲明（“公司”）。這些前瞻性聲明通過使用 “繼續”、“開發”、“預期”、“期待” 和 “擴展” 等詞語來識別。新聞稿中的前瞻性聲明受到公司業務固有的某些風險和不確定性的影響，這可能導致實際結果有所不同，包括監管臨牀和指導方針的發展可能會發生變化，科學數據可能不足以滿足監管標準或獲得所需的監管許可或批准，臨牀結果可能無法在實際患者環境中複製，公司專利和專利申請所提供的保護可能會受到競爭對手的挑戰、無效或規避，公司產品的可用市場可能沒有預期的那麼大，公司產品可能無法進入一個或多個目標市場，收入可能不足以滿足公司的現金需求，資助進一步開發，滿足不同國家和市政當局的多種監管和市場要求的能力，以及公司在向證券交易委員會提交的文件中不時詳細説明的其他風險。除法律要求外，公司不承擔更新這些前瞻性聲明的任何義務。</p>
<p>Sonoma Pharmaceuticals™和 Microcyn®是 Sonoma Pharmaceuticals, Inc.的商標或註冊商標。所有其他商標和服務標誌均為其各自所有者的財產。</p>
<p><strong>媒體和投資者聯繫：</strong></p>
<p>Sonoma Pharmaceuticals, Inc.</p>
<p>ir@sonomapharma.com</p>
<p><strong>來源：</strong> Sonoma Pharmaceuticals, Inc.</p>
<p>查看原始新聞稿，請訪問 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTE2MDg5NA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTE2MDg5NA"/></p>

Sonoma制藥

標普生物技術 ETF - SPDR

生物科技 ETF - VanEck Vectors

<p>Sonoma Pharmaceuticals, Inc.（納斯達克代碼：SNOA）宣佈了一項公開發行的定價，預計將籌集約 400 萬美元。此次發行包括 2,962,963 股普通股和認股權證，每股定價為 1.35 美元。Dawson James Securities 是唯一的賬簿管理人，發行預計將在 2026 年 4 月 27 日完成，具體取決於常規條件。籌集的資金將用於一般企業用途。已向美國證券交易委員會（SEC）提交了註冊聲明，發行僅通過招股説明書進行</p>

<p>Sonoma Pharmaceuticals, Inc. (the &#34;Company&#34; or &#34;Sonoma Pharmaceuticals&#34;) (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced the pricing of its public offering made on a firm commitment basis with gross proceeds to the Company expected to be approximately $4.0 million, before deducting fees and other expenses payable by the Company. The offering consists of 2,962,963 shares of common stock and 2,962,963 warrants. Each share of common stock is being sold at a purchase price of $1.35 per share. The warrants have an exercise price of $1.35 per share.</p>
<div class="lb-trans"><p>Sonoma Pharmaceuticals, Inc.（“公司” 或 “Sonoma Pharmaceuticals”）（NASDAQ:SNOA）是一家全球領先的次氯酸（HOCl）技術醫療保健公司，今天宣佈其公開發行的定價，該發行以固定承諾的方式進行，預計公司將獲得約 400 萬美元的總收益，未扣除公司需支付的費用和其他開支。此次發行包括 2,962,963 股普通股和 2,962,963 個認股權證。每股普通股的銷售價格為 1.35 美元。認股權證的行使價格為每股 1.35 美元。</p>
</div><p>In addition, Sonoma Pharmaceuticals has granted Dawson James Securities a 45-day option to purchase up to 15% of the number of shares or warrants sold in the offering solely to cover over-allotments, if any.</p>
<div class="lb-trans"><p>此外，Sonoma Pharmaceuticals 已授予 Dawson James Securities 一個為期 45 天的選擇權，以購買最多 15% 在此次發行中出售的股份或認股權證，僅用於覆蓋超額配售（如有）。</p>
</div><p>The offering is expected to close on April 27, 2026, subject to the satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>此次發行預計將於 2026 年 4 月 27 日完成，前提是滿足慣常的交割條件。</p>
</div><p>The Company expects to use the net proceeds from the offering for general corporate purposes, including working capital.</p>
<div class="lb-trans"><p>公司預計將把此次發行的淨收益用於一般企業用途，包括營運資金。</p>
</div><p>Dawson James Securities is acting as sole bookrunner for the offering.</p>
<div class="lb-trans"><p>Dawson James Securities 擔任此次發行的唯一賬簿管理人。</p>
</div><p>A registration statement on Form S-1 relating to the offering of the securities was filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on April 23, 2026. The offering is being made only by means of a prospectus. A final prospectus describing the terms of the proposed transaction may be obtained, when available, on the SEC's website, www.sec.gov or by contacting Dawson James Securities. This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>與此次證券發行相關的 S-1 表格註冊聲明已向美國證券交易委員會（SEC）提交，並於 2026 年 4 月 23 日獲得 SEC 的有效聲明。此次發行僅通過招股説明書進行。有關擬議交易條款的最終招股説明書可在 SEC 的網站 www.sec.gov 上獲取，或通過聯繫 Dawson James Securities 獲取。本新聞稿不構成出售這些證券的要約或購買這些證券的要約邀請，也不應在任何州或司法管轄區進行證券的銷售，除非在任何此類州或司法管轄區的證券法下進行註冊或資格審查。</p>
</div><p><strong>About Sonoma Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>關於 Sonoma Pharmaceuticals</strong></p>
</div><p>Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com.</p>
<div class="lb-trans"><p>Sonoma Pharmaceuticals 是一家全球醫療保健領導者，專注於開發和生產穩定的次氯酸（HOCl）產品，廣泛應用於傷口護理、眼部護理、皮膚病、足病、動物醫療和無毒消毒劑。Sonoma 的產品經過臨牀驗證，能夠安全有效地減少瘙癢、疼痛、疤痕和刺激，而不會損害健康組織。對 HOCl 的體外和臨牀研究表明，它能夠安全管理皮膚擦傷、裂傷、輕微刺激、切口和完整皮膚。Sonoma 的產品在全球 55 個國家通過直接銷售或合作伙伴銷售，公司積極尋求新的分銷合作伙伴。公司的主要辦公室位於科羅拉多州博爾德，製造業務位於墨西哥瓜達拉哈拉。歐洲市場營銷和銷售總部位於荷蘭羅 ermond。更多信息請訪問 www.sonomapharma.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the &#34;safe harbor&#34; provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the &#34;company&#34;). These forward-looking statements are identified by the use of words such as &#34;continue,&#34; &#34;develop,&#34; &#34;anticipate,&#34; &#34;expect&#34; and &#34;expand,&#34; among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, the ability to meet a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.</p>
<div class="lb-trans"><p>除本文中的歷史信息外，本新聞稿中所述事項屬於 1995 年《私人證券訴訟改革法案》“安全港” 條款下的前瞻性聲明，包括關於 Sonoma Pharmaceuticals, Inc.及其子公司的商業和技術進展及未來財務表現的聲明（“公司”）。這些前瞻性聲明通過使用 “繼續”、“開發”、“預期”、“期待” 和 “擴展” 等詞語來識別。新聞稿中的前瞻性聲明受到公司業務固有的某些風險和不確定性的影響，這可能導致實際結果有所不同，包括監管臨牀和指導方針的發展可能會發生變化，科學數據可能不足以滿足監管標準或獲得所需的監管許可或批准，臨牀結果可能無法在實際患者環境中複製，公司專利和專利申請所提供的保護可能會受到競爭對手的挑戰、無效或規避，公司產品的可用市場可能沒有預期的那麼大，公司產品可能無法進入一個或多個目標市場，收入可能不足以滿足公司的現金需求，資助進一步開發，滿足不同國家和市政當局的多種監管和市場要求的能力，以及公司在向證券交易委員會提交的文件中不時詳細説明的其他風險。除法律要求外，公司不承擔更新這些前瞻性聲明的任何義務。</p>
</div><p>Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.</p>
<div class="lb-trans"><p>Sonoma Pharmaceuticals™和 Microcyn®是 Sonoma Pharmaceuticals, Inc.的商標或註冊商標。所有其他商標和服務標誌均為其各自所有者的財產。</p>
</div><p><strong>Media and Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>媒體和投資者聯繫：</strong></p>
</div><p>Sonoma Pharmaceuticals, Inc.</p>
<div class="lb-trans"><p>Sonoma Pharmaceuticals, Inc.</p>
</div><p>ir@sonomapharma.com</p>
<div class="lb-trans"><p>ir@sonomapharma.com</p>
</div><p><strong>SOURCE:</strong> Sonoma Pharmaceuticals, Inc.</p>
<div class="lb-trans"><p><strong>來源：</strong> Sonoma Pharmaceuticals, Inc.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新聞稿，請訪問 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTE2MDg5NA" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1160894"/></p>

Sonoma 製藥宣佈 400 萬美元公開發行的定價 | SNOA 股票新聞